Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion

被引:49
|
作者
Wang, EX
Sun, X
Qian, Y
Zhao, LQ
Tien, P
Gao, GF
机构
[1] Chinese Acad Sci, Inst Microbiol, Dept Mol Virol & Bioengn, Beijing 100080, Peoples R China
[2] Capital Inst Pediat, Beijing Municipal Lab Infect & Immun, Beijing 100020, Peoples R China
[3] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
关键词
human respiratory syncytial virus; hRSV; virus fusion; fusion (F) protein; coiled coil; heptad repeats; inhibition;
D O I
10.1016/S0006-291X(03)00197-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heptad repeat regions (HR1 and HR2) are highly conserved peptides located in F-1 of paramyxovirus envelope proteins. They are important in the process of virus fusion and form six-helix bundle structure (trimer of HR1 and HR2 heterodimer) post-fusion, similar to those found in the fusion proteins of other enveloped viruses, such as retrovirus HIV. Both HR1 and HR2 show potent inhibition for virus fusion in some members of paramyxovirus. However, in other members, only HR2 gives strong inhibition whereas HR1 does not. Human respiratory syncytial virus (hRSV) is a member of paramyxovirus and its crystal structure of HR1 and HR2 six-helix bundle was solved lately. Although hRSV HR2 inhibition was reported, nevertheless the effect of HR1 on virus fusion is not known. In this study, hRSV HR1 and HR2 were expressed as fusion protein separately in Escherichia coli system and their complex assembly and virus fusion inhibition effect have been analysed. It shows that both HR1 and HR2 (in the fusion form with 50-amino-acid fusion partner) of hRSV F protein give strong inhibition on virus fusion (IC50 values are 1.68 and 2.93 muM, respectively) and they form stable six-helix bundle in vitro with both in the fusion protein form. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:469 / 475
页数:7
相关论文
共 50 条
  • [21] Novel and specific respiratory syncytial virus inhibitors that target virus fusion
    Ding, WD
    Mitsner, B
    Krishnamurthy, G
    Aulabaugh, A
    Hess, CD
    Zaccardi, J
    Cutler, M
    Feld, B
    Gazumyan, A
    Raifeld, Y
    Nikitenko, A
    Lang, SA
    Gluzman, Y
    O'Hara, B
    Ellestad, GA
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (15) : 2671 - 2675
  • [22] Purification of human respiratory syncytial virus fusion glycoprotein
    Zheng, Yanpeng
    Tang, Yaning
    Fu, Yuanhui
    He, Jinsheng
    Wang, Xiaobo
    Hong, Tao
    PROTEIN EXPRESSION AND PURIFICATION, 2012, 81 (01) : 115 - 118
  • [23] Molecular evolution of the fusion protein gene in human respiratory syncytial virus subgroup A
    Kimura, Hirokazu
    Nagasawa, Koo
    Tsukagoshi, Hiroyuki
    Matsushima, Yuki
    Fujita, Kiyotaka
    Yoshida, Lay Myint
    Tanaka, Ryota
    Ishii, Haruyuki
    Shimojo, Naoki
    Kuroda, Makoto
    Ryo, Akihide
    INFECTION GENETICS AND EVOLUTION, 2016, 43 : 398 - 406
  • [24] Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein
    Leemans, A.
    De Schryver, M.
    Van der Gucht, W.
    Heykers, A.
    Pintelon, I.
    Hotard, A. L.
    Moore, M. L.
    Melero, J. A.
    McLellan, J. S.
    Graham, B. S.
    Broadbent, L.
    Power, U. F.
    Caljon, G.
    Cos, P.
    Maes, L.
    Delputte, P.
    JOURNAL OF VIROLOGY, 2017, 91 (14)
  • [25] Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor
    Zheng, Xiufang
    Gao, Lu
    Wang, Lisha
    Liang, Chungen
    Wang, Baoxia
    Liu, Yongfu
    Feng, Song
    Zhang, Bo
    Zhou, Mingwei
    Yu, Xin
    Xiang, Kunlun
    Chen, Li
    Guo, Tao
    Shen, Hong C.
    Zou, Gang
    Wu, Jim Zhen
    Yun, Hongying
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (13) : 6003 - 6014
  • [26] Inhibitors of respiratory syncytial virus fusion: Optimization from screening leads to potent, orally active compounds
    Meanwell, Nicholas A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [27] Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors
    Zheng, Xiufang
    Liang, Chungen
    Wang, Lisha
    Wang, Baoxia
    Liu, Yongfu
    Feng, Song
    Wu, Jim Zhen
    Gao, Lu
    Feng, Lichun
    Chen, Li
    Guo, Tao
    Shen, Hong C.
    Yun, Hongying
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (22) : 10228 - 10241
  • [28] Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion
    González-Reyes, L
    Ruiz-Argüello, MB
    García-Barreno, B
    Calder, L
    López, JA
    Albar, JP
    Skehel, JJ
    Wiley, DC
    Melero, JA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) : 9859 - 9864
  • [29] Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors
    Zheng, Xiufang
    Wang, Lisha
    Wang, Baoxia
    Miao, Kun
    Xiang, Kunlun
    Feng, Song
    Gao, Lu
    Shen, Hong C.
    Yun, Hongying
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (06): : 558 - 562
  • [30] Respiratory syncytial virus - the discovery and optimization of orally bioavailable fusion inhibitors
    Meanwell, Nicholas A.
    Krystal, Mark
    DRUGS OF THE FUTURE, 2007, 32 (05) : 441 - 455